Stock Graphs and Charts

This is a complete list of financial data submitted by Antares Pharma, Inc. to the Securities and Exchange Commission (SEC) in their recent 10K and 10Q filings. These terms are taken from the XBRL portion of the filings.

Click on a term to see historical data and generate a time series chart from the historical filings.

Term
Accounts Payable Current
Accounts Receivable Net Current
Accretion Amortization Of Discounts And Premiums Investments
Accretion Expense
Accrued Liabilities Current
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Accumulated Other Comprehensive Income Loss Net Of Tax
Additional Paid In Capital Common Stock
Additions To Patent Rights Recorded In Accounts Payable And Accrued Expenses
Adjustment For Amortization
Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Allocated Share Based Compensation Expense
Allowance For Doubtful Accounts Receivable Current
Allowance For Doubtful Accounts Receivable Write Offs
Amortization Of Financing Costs
Amortization Of Financing Costs And Discounts
Amortization Of Intangible Assets
Amount Of Net Operating Loss Carryforwards Used To Offset Taxable Income
Anticipated Cash Flow From Patents Due To Agreement
Anticipated Revenues From Patents Due To Agreement
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Asset Impairment Charges
Assets
Assets Current
Basic And Diluted Weighted Average Common Shares Outstanding
Business Development
Capital Expenditures Incurred But Not Yet Paid
Capitalized Legal Patent Costs
Capital Stock Shares Authorized
Cash
Cash And Cash Equivalents At Carrying Value
Cash And Cash Equivalents Period Increase Decrease
Cash Cash Equivalents And Short Term Investments
Cash Discount Percent
Cash Period Increase Decrease
Class Of Warrant Or Right Cancelled
Class Of Warrant Or Right Exercised
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
Class Of Warrant Or Right Outstanding
Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
Common Shares Outstanding
Common Stock Par Or Stated Value Per Share
Common Stock Shares Authorized
Common Stock Shares Issued
Common Stock Shares Outstanding
Common Stock Value Outstanding
Comprehensive Income Net Of Tax
Contract Revenue Cost
Contracts Revenue
Conversion Gains And Losses On Foreign Investments
Cost Of Goods Sold
Cost Of Revenue
Cost Of Services
Deferred Costs
Deferred Costs Current
Deferred Gain On Sale Of Assets Current
Deferred Revenue
Deferred Revenue Current
Deferred Revenue Noncurrent
Deferred Tax Assets Deferred Income
Deferred Tax Assets Gross
Deferred Tax Assets Gross Depreciation And Amortization
Deferred Tax Assets Inventory
Deferred Tax Assets Net
Deferred Tax Assets Operating Loss Carryforwards Domestic
Deferred Tax Assets Operating Loss Carryforwards Foreign
Deferred Tax Assets Other
Deferred Tax Assets Tax Credit Carryforwards Research
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
Deferred Tax Assets Valuation Allowance
Deferred Tax Liabilities Depreciation And Amortization
Defined Contribution Plan Employer Discretionary Contribution Amount
Defined Contribution Plan Maximum Annual Contribution Per Employee Percent
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
Depreciation
Depreciation Depletion And Amortization
Dissolution Of Foreign Subsidiary
Earnings Per Share Basic And Diluted
Effective Income Tax Rate Continuing Operations
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
Effective Income Tax Rate Reconciliation Expiration Of Unused Net Operating Loss And Credit Carry Forwards
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
Effective Income Tax Rate Reconciliation Nondeductible Expense
Effective Income Tax Rate Reconciliation Other Adjustments
Effective Income Tax Rate Reconciliation State And Local Income Taxes
Effect Of Exchange Rate On Cash
Effect Of Exchange Rate On Cash And Cash Equivalents
Employee Related Liabilities Current
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
Entity Wide Accounts Receivable Major Customer Percentage
Entity Wide Revenue Major Customer Percentage
Expense For Removing Cumulative Translation Adjustment From Other Comprehensive Income
Finite Lived Intangible Assets Accumulated Amortization
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
Finite Lived Intangible Assets Amortization Expense Year Five
Finite Lived Intangible Assets Amortization Expense Year Four
Finite Lived Intangible Assets Amortization Expense Year Three
Finite Lived Intangible Assets Amortization Expense Year Two
Finite Lived Intangible Assets Net
Finite Lived Intangible Assets Net Transferred
Finite Lived Patents Gross
Foreign Currency Transaction Gain Loss Before Tax
Gain Loss On Disposition Of Assets1
Gain Loss On Sale Of Property Plant Equipment
General And Administrative Expense
Goodwill
Goodwill Impairment Loss
Gross Profit
Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value
Held To Maturity Securities Debt Maturities Within One Year Fair Value
Income Loss From Continuing Operations Before Income Taxes Domestic
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
Income Loss From Continuing Operations Before Income Taxes Foreign
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
Income Loss From Continuing Operations Per Basic And Diluted Share
Income Tax Expense Benefit
Increase Decrease In Accounts Payable
Increase Decrease In Accounts Receivable
Increase Decrease In Accrued Liabilities
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
Increase Decrease In Deferred Charges
Increase Decrease In Deferred Revenue
Increase Decrease In Inventories
Increase Decrease In Inventory Reserve
Increase Decrease In Notes Payable Current
Increase Decrease In Other Operating Assets
Increase Decrease In Prepaid Deferred Expense And Other Assets
Initial Cash Receipts Recognized And Unrecognized Deferred Revenue
Interest Expense
Interest Income Operating
Inventory Finished Goods
Inventory Finished Goods Net Of Reserves
Inventory Net
Inventory Raw Materials
Inventory Raw Materials Net Of Reserves
Inventory Valuation Reserves
Inventory Work In Process
Inventory Work In Process Net Of Reserves
Inventory Write Down
Investments
Investments Fair Value Disclosure
Land Subject To Ground Leases
Liabilities
Liabilities And Stockholders Equity
Liabilities Current
Licenses Revenue
Licensing And Development Revenue
Long Term Debt
Long Term Debt Maturities Repayments Of Principal After Year Five
Long Term Debt Maturities Repayments Of Principal In Year Five
Long Term Debt Maturities Repayments Of Principal In Year Four
Long Term Debt Maturities Repayments Of Principal In Year Three
Long Term Debt Maturities Repayments Of Principal In Year Two
Long Term Debt Noncurrent
Long Term Investments
Loss On Dissolution Of Foreign Subsidiary
Market Capitalization Of Company
Maximum Percentage Of Exercise Price Over Market Price Of Granted Date
Minimum Percentage Of Exercise Price Over Market Price Of Granted Date
Molds And Tooling In Process
Net Cash Provided By Used In Financing Activities
Net Cash Provided By Used In Financing Activities Continuing Operations
Net Cash Provided By Used In Investing Activities
Net Cash Provided By Used In Investing Activities Continuing Operations
Net Cash Provided By Used In Operating Activities
Net Cash Provided By Used In Operating Activities Continuing Operations
Net Income Loss
Net Income Loss Available To Common Stockholders Basic
Net Proceeds After Deducting Underwriting Commissions And Estimated Offering Expenses Payable
Nonoperating Income Expense
Non Refundable Up Front Payment
Number Of Facility Locations
Number Of Investigative Sites
Number Of Operating Segments
Number Of Patents
Number Of Patients Enrolled In Study
Number Of Primary Customers
Number Of Product Candidates In Advanced Stages Of Development
Number Of Subsidiaries Dissolved
Number Of Undisclosed Patient Administered Pharmaceutical Products
Number Of Wholly Owned Subsidiaries
Operating Expenses
Operating Income Loss
Operating Leases Future Minimum Payments Due
Operating Leases Future Minimum Payments Due Current
Operating Leases Future Minimum Payments Due In Five Years
Operating Leases Future Minimum Payments Due In Four Years
Operating Leases Future Minimum Payments Due In Three Years
Operating Leases Future Minimum Payments Due In Two Years
Operating Leases Future Minimum Payments Due Thereafter
Operating Leases Rent Expense Net
Operating Loss Carryforwards Unused Amount
Operating Loss Carryforwards Utilized
Other Accrued Liabilities Current
Other Assets Noncurrent
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
Other Comprehensive Income Loss Net Of Tax
Other Nonoperating Expense
Other Nonoperating Income Expense
Other Sales Revenue Net
Patent Legal Costs
Payments Of Debt Issuance Costs
Payments Related To Tax Withholding For Share Based Compensation
Payments To Acquire Intangible Assets
Payments To Acquire Investments
Payments To Acquire Property Plant And Equipment
Percentage Of Gross Accounts Receivable Due From Largest Customers
Percentage Of Gross Accounts Receivable Due From Two Largest Customers
Performance Stock Units Delivered To Officer
Preferred Stock Par Or Stated Value Per Share
Preferred Stock Shares Authorized
Preferred Stock Shares Outstanding
Preferred Stock Value Outstanding
Prepaid Expense And Other Assets Current
Proceeds From Exercise Of Warrants And Stock Options
Proceeds From Issuance Of Common Stock
Proceeds From Issuance Of Long Term Debt
Proceeds From Sale Maturity And Collection Of Shortterm Investments
Proceeds From Sale Of Machinery And Equipment
Proceeds From Sale Of Productive Assets
Proceeds From Sale Of Property Plant And Equipment
Proceeds From Stock Options Exercised
Production Molds And Equipment
Product Warranty Accrual
Product Warranty Accrual Payments
Product Warranty Accrual Warranties Issued
Property Plant And Equipment Gross
Property Plant And Equipment Net
Provision For Doubtful Accounts
Recognition Of Deferred Revenue
Research And Development Expense
Retained Earnings Accumulated Deficit
Revenue From Contract With Customer Excluding Assessed Tax
Revenue Recognition Multiple Deliverable Arrangements Revenue Deferred
Revenue Recognized In Connection With Manufacturing Start Up Activities
Revenue Remaining Performance Obligation
Revenues
Revenues From External Customers
Royalty And Licensing Revenue
Royalty Revenue
Sales Revenue Goods Net
Sales Revenue Services Net
Selling And Marketing Expense
Selling General And Administrative Expense
Share Based Compensation
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Share Based Compensation Arrangement By Share Based Payment Award Stock Option Delivered To Officer
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Share Price
Shares Float
Shares Paid For Tax Withholding For Share Based Compensation
Short Term Investments
Square Footage Of Building Under Lessee Operating Lease
Stockholders Equity
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
Stock Issued During Period Shares New Issues
Stock Issued During Period Shares Stock Options Exercised
Stock Issued During Period Shares Stock Options Exercised Gross
Stock Issued During Period Value New Issues
Stock Issued During Period Value Share Based Compensation
Stock Issued During Period Value Stock Options Exercised
Stock Issued During Period Value Warrants And Stock Options Exercised
Stock Issued During Period Value Warrants Exercised
Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Assets Provisional Income Tax Benefit
Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Valuation Allowance
Unrecognized Tax Benefits
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
Valuation Allowance Deferred Tax Asset Change In Amount
Warrant Exercises In Period Weighted Average Exercise Price
Warrants And Options Exercised
Warrants Cancelled Weighted Average Exercise Price
Weighted Average Number Of Share Outstanding Basic And Diluted
Weighted Average Number Of Shares Outstanding Basic

Peers - Surgical and Medical Instruments and Apparatus (3841)

Related News Stories

Swinging For The Fence On Antares Pharma

2018-07-08 seekingalpha
A study from 2009 by Alok Kumar found retail investors exhibit “a greater propensity to gamble” as compared to institutional investors. (62-1)

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

2018-06-07 seekingalpha
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested. (627-6)

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

2018-05-31 seekingalpha
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme. (666-4)

Redux: My 3 January Effect Candidates Are Producing Major Alpha Through May

2018-05-30 seekingalpha
Back in early January my article "3 Biotechs For The January Effect" was published. The article highlighted Geron (GERN), Antares Pharma (ATRS) and AcelRX (ACRX). This article is to assess my picks so far in May and outline prospects going forward to determine if we should sell, hold or buy more. Thus far, all three well overperformed both the Nasdaq (QQQ) as well as their small biotech (SBIO) peer group. (75-1)

Antares Pharma, Excellent Risk-Reward Profile

2018-05-22 seekingalpha
Company remains a viable acquisition candidate, especially in the likely aftermath of Xyosted being approved by the FDA. (68-0)

CUSIP: 036642106